Get the real deal on beauty treatments—real doctors, real reviews, and real photos with real results.Here's how we earn your trust.
Thank you foryour question star2312. Kybella is the first andthus-far only FDA-approved non-surgical injectable treatment for the doublechin. I am not aware of its availability overseas. However in other countries it is distributed as Belkyra. Pleaseconsult with a doctor for specific recommendations. Good luck!
Hello Star2312,Kybella is currently only for sale in the US. It does require a series of injections spaced about 6 weeks apart which would make travel quite difficult traveling from Greece. You may consider contacting the company Allergan that makes it to see if they are in the process of receiving European approval.I hope this helps and good luck.
Unfortunately, Kybella is only available in the United States for now. Wish I had better news as it is an extremely effective procedure for the right patient.
Kybella is a great procedure that contours and improves the appearance of moderate to severe fat under the chin known. However, as of right now it is only available in the United States.Best,Dr. Green
For uncomplicated liposuction under the chin (submental suction lipectomy), we charge $2750. This includes the preoperative appointment, procedure, and all postoperative followups. We have laughing gas available for $50. The procedure requires a single 4 mm (less than 1/4") incision and tak...
Kybella is safe to use and it is FDA approved. It is injected in your tissue in the chin and neck area, and it works by dissolving fat. Since it is injected in the tissue it can not migrate to your brain, heart or some areas of your face. There are some side effects that can occur after Kybella...
Thank you for your question aresbany. Kybella is the first and thus-far only FDA-approved non-surgical injectable treatment for the double chin. Kybella can be administered by any physician which has appropriate training. A series of 2-4 treatments is recommended, sometimes up to 6 treatments. I...
